A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Yi-Long Wu¹, Chang-Li Wang², Yan Sun³, Mei-Lin Liao⁴, Zhong-Zhen Guan⁵, Zhi-Min Yang⁶, Qing-Hua Zhou⁷, Shun Lu⁴, Ying Cheng⁸, Xiao-Qing Liu⁹, Xu-Chao Zhang¹⁰, Caicun Zhou¹¹, Jie Wang¹², Qing Zhou¹⁰, Yong Song¹³, Bao-Hui Han¹⁴, Zhi-Yong Ma¹⁵, Fan Yang¹⁶, Qun Wang¹⁷, Shao-Kun Chuai¹⁸, Yang Shao¹⁹, Wei He²⁰, Guanshan Zhu²¹, Lei Xiong²², Jian-Jun Wang²³, Ke-Neng Chen²⁴, Li Zhang⁵, Wei-Min Mao²⁵, Sheng-Lin Ma²⁶, Ji-Feng Feng²⁷, Xue-Ning Yang¹⁰, Lin Xu²⁸, Gang Chen¹⁰, Jian Zhao²⁹, Qi-Bin Song³⁰, Yang Shen-Tu⁴, Gui-Bin Qiao³¹, Ding Yu³², Shi-Ying Yu³³, Yi Hu³⁴, Ming Chen³⁵, Gong-Yan Chen³⁶, Yun Fan³⁷, He-Long Zhang³⁸, Jun Liang¹², Guang-Ying Zhu³⁹, Jiu-Wei Cui⁴⁰, Jin-Ji Yang¹⁰, Qiong Zhao⁴¹, Ming-Fang Zhao⁴², You Lu⁴³, Jian-Hua Chang⁴⁴, Jun-Ling Li¹², Yue Yang⁴⁵, Jie Hu⁴⁶, Chun-Dong Gu⁴⁷, Yi-Chen Zhang¹⁰, Wen-Zhao Zhong¹⁰

Affiliations

¹ Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address: syylwu@gmail.com.
² Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
³ National GCP Center for Anticancer Agents, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁴ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
⁵ Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
⁶ The Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
⁷ Lung Cancer Center, West China Hospital, Chengdu, China.
⁸ Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
⁹ Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing, China.
¹⁰ Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
¹¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
¹² Department of Medical Oncology, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹³ Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
¹⁴ Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
¹⁵ Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
¹⁶ Department of Thoracic Surgery, Peking University People Hospital, Beijing, China.
¹⁷ Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
¹⁸ Burning Rock Biotech, Guangzhou, China.
¹⁹ Geneseeq Technology Inc, Nanjing, China; College of Basic Medicine, Nanjing Medical University, Nanjing, China.
²⁰ Geno Biotech Co Ltd, Shanghai, China.
²¹ R&D department, Amoy Diagnostics, Xiamen, China.
²² 3D Medicines, Shanghai, China.
²³ Department of thoracic surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²⁴ Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing, China.
²⁵ Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
²⁶ Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China.
²⁷ Department of Chemotherapy, Jiangsu Cancer Hospital, Nanjing, China.
²⁸ Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing, China.
²⁹ Department of Chest Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
³⁰ Cancer Center of Renmin Hospital, Wuhan University, Wuhan, China.
³¹ Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou, China.
³² Oncology Medicine Department, Hubei Cancer Hospital, Wuhan, China.
³³ Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
³⁴ Department of Internal Oncology, 301 General Hospital, Beijing, China.
³⁵ Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
³⁶ Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
³⁷ Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
³⁸ Department of Medical Oncology, Tangdu Hospital, Xian, China.
³⁹ Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
⁴⁰ Cancer Center, The First Hospital of Jilin University, Changchun, China.
⁴¹ Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou, China.
⁴² Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
⁴³ Department of Thoracic Cancer, West China Hospital, Chengdu, China.
⁴⁴ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁴⁵ Department of Thoracic Surgery II, Peking University Cancer Hospital and Institute, Beijing, China.
⁴⁶ Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
⁴⁷ Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

PMID: 28848676
PMCID: PMC5559904
DOI: 10.1136/esmoopen-2017-000174

Review

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Yi-Long Wu et al. ESMO Open. 2017.

. 2017 Apr 4;2(Suppl 1):e000174.

doi: 10.1136/esmoopen-2017-000174. eCollection 2017.

Authors

Affiliations

¹ Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address: syylwu@gmail.com.
² Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
³ National GCP Center for Anticancer Agents, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁴ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
⁵ Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
⁶ The Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
⁷ Lung Cancer Center, West China Hospital, Chengdu, China.
⁸ Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
⁹ Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing, China.
¹⁰ Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
¹¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
¹² Department of Medical Oncology, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹³ Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
¹⁴ Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
¹⁵ Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
¹⁶ Department of Thoracic Surgery, Peking University People Hospital, Beijing, China.
¹⁷ Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
¹⁸ Burning Rock Biotech, Guangzhou, China.
¹⁹ Geneseeq Technology Inc, Nanjing, China; College of Basic Medicine, Nanjing Medical University, Nanjing, China.
²⁰ Geno Biotech Co Ltd, Shanghai, China.
²¹ R&D department, Amoy Diagnostics, Xiamen, China.
²² 3D Medicines, Shanghai, China.
²³ Department of thoracic surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²⁴ Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing, China.
²⁵ Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
²⁶ Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China.
²⁷ Department of Chemotherapy, Jiangsu Cancer Hospital, Nanjing, China.
²⁸ Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing, China.
²⁹ Department of Chest Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
³⁰ Cancer Center of Renmin Hospital, Wuhan University, Wuhan, China.
³¹ Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou, China.
³² Oncology Medicine Department, Hubei Cancer Hospital, Wuhan, China.
³³ Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
³⁴ Department of Internal Oncology, 301 General Hospital, Beijing, China.
³⁵ Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
³⁶ Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
³⁷ Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
³⁸ Department of Medical Oncology, Tangdu Hospital, Xian, China.
³⁹ Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
⁴⁰ Cancer Center, The First Hospital of Jilin University, Changchun, China.
⁴¹ Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou, China.
⁴² Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
⁴³ Department of Thoracic Cancer, West China Hospital, Chengdu, China.
⁴⁴ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁴⁵ Department of Thoracic Surgery II, Peking University Cancer Hospital and Institute, Beijing, China.
⁴⁶ Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
⁴⁷ Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

PMID: 28848676
PMCID: PMC5559904
DOI: 10.1136/esmoopen-2017-000174

Abstract

The diagnosis and treatment of lung cancer have evolved into the era of precision medicine. Liquid biopsy, a minimally invasive approach, has emerged as a promising practice in genetic profiling and monitoring of lung cancer. Translating liquid biopsy from bench to bedside has encountered various challenges, including technique selection, protocol standardisation, data analysis and cost management. Regarding these challenges, the 2016 Chinese Lung Cancer Summit expert panel organised a trilateral forum involving oncologists, clinicians, clinical researchers, and industrial expertise on the 13th Chinese Lung Cancer Summit to formally discuss these controversies. Six consensuses were reached to guide the use of liquid biopsy and perform precision medicine in both clinic and research.

Keywords: Liquid biopsy; lung cancer; next-generation sequencing.

PubMed Disclaimer

Conflict of interest statement

Competing interests: S-KC is from Burning Rock Biotech. YS is from Geneseeq Technology Inc. WH is from Geno Biotech. G-SZ is from Amoy Diagnostics. LX is from 3D Medicines.

Figures

**Figure 1**
Survey on whether NGS could replace the role of single gene detection in clinical practice. NGS, next-generation sequencing.

**Figure 2**
Survey on when NGS-based genetic testing can be used in clinical practice. NGS, next-generation sequencing.

See this image and copyright information in PMC

References

1. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015;372:2229–34.10.1056/NEJMsb1503104 - DOI - PubMed
1. Soda M, Choi YL, Enomoto M, et al. . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.10.1038/nature05945 - DOI - PubMed
1. Kwak EL, Camidge DR, Clark J, et al. . Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27:3509.
1. Camidge DR, Bang YJ, Kwak EL, et al. . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011–9.10.1016/S1470-2045(12)70344-3 - DOI - PMC - PubMed
1. Kim D-W, Ahn M-J, Shi Y, et al. . Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung Cancer [abstract]. J Clin Oncol 2012;30(Suppl 15; Abstr 7533).

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Affiliations

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources